Skip to main content

Table 2 Characteristics of individual patients

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

No-TACE

Patient Number

Age

Gender

Etiology

AFP

# Tumors at Dx

Size (cm) pre-op

Within Milan

Growth rate (cm/mo.)

Largest tumor dia by path

Days to Transplant*

Recur

Time to Recur

Reasons not to TACE

A

B

C

D

E

N1

62

F

HCV

20

2

1.9, 1.6

Y

N/A

1.6

49

N

N/A

X

    

N2

48

M

HCV

13

1

1.9

Y

N/A

2

340

N

N/A

X

    

N3

49

F

HCV

1207

3

1.3, 2.0, 2.5

Y

N/A

3.4

188

N

N/A

X

    

N4

52

F

HCV

107

2

1.0, 2.1

Y

N/A

2.3

160

N

N/A

X

    

N5

65

M

HCV

5.3

2

N/A

N/A

N/A

1.1

12

N

N/A

   

X

 

N6

56

M

HBV

4

1

4.8

Y

N/A

3.5

59

N

N/A

X

    

N7

68

M

HCV

1327

2

1.4, 2.6

Y

0.12

2.8

205

N

N/A

    

X

N8

46

F

HCV

2809

1

3.8

Y

0.2

6

115

N

N/A

X

 

X

  

N9

48

M

HCV

686

1

3

Y

0.4

3.6

116

N

N/A

X

    

N10

53

M

HCV

3

1

1.5

Y

0.1

2.5

190

N

N/A

X

    

N11

45

M

HCV

4

1

5.4

N

N/A

5.1

45

N

N/A

 

X

   

N12

57

M

HCV

6

1

2.8

Y

N/A

4

41

Y

24mo.

X

    

N13

55

M

HCV

11

2

0.9, 1.6

Y

N/A

2.3

38

N

N/A

X

    

N14

49

M

HCV

7

1

5.3

N

N/A

5.5

87

N

N/A

 

X

   

N15

53

M

HCV

2461

1

2.8

Y

N/A

5

95

N

N/A

X

    

N16

55

M

HCV

7

2

1.0, 0.8

Y

N/A

1

0

N

N/A

   

X

 

N17

52

M

HCV

18

1

2.5

Y

N/A

3.1

128

N

N/A

X

 

X

  

N18

56

F

HCV

19

1

3.3

Y

N/A

3.5

117

N

N/A

X

 

X

  

N19

68

M

HCV

9

2

2.2, 1.6

Y

0

2

377

N

N/A

X

 

X

  

N20

56

M

HCV

7

1

N/A

N/A

N/A

1

0

N

N/A

   

X

 

N21

53

M

PSC

40

2

N/A

N/A

N/A

0.3

0

N

N/A

   

X

 

N22

64

M

HCV

20

1

2.1

Y

N/A

3.5

179

N

N/A

X

    

N23

49

M

HCV

3.6

1

N/A

N/A

N/A

1.5

0

N

N/A

   

X

 
  1. A = Patient was within Milan.
  2. B = Outside Milan but eligible for transplant by MELD with a short waiting time expected.
  3. C = Patient could not tolerate procedure.
  4. D = Tumor not appreciated pre-op.
  5. E = Procedure planned, not able to perform prior to transplant.
  6. * = Days from HCC diagnosis to transplant.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us